1. United Nations Office on Drugs, & Crime. 2005 World drug report (Vol. 2). United Nations Publications; 2005.

2. Darke S, Torok M, McKetin R, Kaye S, Ross J. Patterns of psychological distress related to regular methamphetamine and opioid use. Addiction Res Theory. 2011;19:121–7.

3. Su H, Zhang J, Ren W, Xie Y, Tao J, Zhang X, et al. Anxiety level and correlates in methamphetamine-dependent patients during acute withdrawal. Medicine. 2017;96:e6434.

4. Hellem TL. A review of methamphetamine dependence and withdrawal treatment: a focus on anxiety outcomes. J Subst Abus Treat. 2016;71:16–22.

5. Morley KC, Cornish JL, Faingold A, Wood K, Haber PS. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opin Investigational Drugs. 2017;26:563–78.

6. Carson DS, Cornish JL, Guastella AJ, Hunt GE, McGregor IS. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. Neuropharmacology. 2010;58:38–43.

7. Cox BM, Young AB, See RE, Reichel CM. Sex differences in methamphetamine seeking in rats: impact of oxytocin. Psychoneuroendocrinology. 2013;38:2343–53.

8. Cox BM, Bentzley BS, Regen-Tuero H, See RE, Reichel CM, Aston-Jones G. Oxytocin acts in nucleus accumbens to attenuate methamphetamine seeking and demand. Biol Psychiatry. 2017;81:949–58.

9. Qi J, Yang JY, Wang F, Zhao YN, Song M, Wu CF. Effects of oxytocin on methamphetamine-induced conditioned place preference and the possible role of glutamatergic neurotransmission in the medial prefrontal cortex of mice in reinstatement. Neuropharmacology. 2009;56:856–65.

10. Baracz SJ, Rourke PI, Pardey MC, Hunt GE, McGregor IS, Cornish JL. Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference. Behavioural brain Res. 2012;228:185–93.

11. Everett N, Baracz S, Cornish J. Oxytocin treatment in the prelimbic cortex reduces relapse to methamphetamine-seeking and is associated with reduced activity in the rostral nucleus accumbens core. Pharmacol Biochem Behav. 2019;183:64–71.

12. Bernheim A, Leong KC, Berini C, Reichel CM. Antagonism of mGlu2/3 receptors in the nucleus accumbens prevents oxytocin from reducing cued methamphetamine seeking in male and female rats. Pharmacol Biochem Behav. 2017;161:13–21.

13. Baracz SJ, Everett NA, Cornish JL. The involvement of oxytocin in the subthalamic nucleus on relapse to methamphetamine-seeking behaviour. PloS ONE 2015;10:e0136132.

14. Baracz SJ, Everett NA, McGregor IS, Cornish JL. Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamine‐seeking behaviour in rats. Addiction Biol. 2016;21:316–25.

15. Everett NA, McGregor IS, Baracz SJ, Cornish JL. The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement. Neuropharmacology. 2018;133:1–11.

16. Ferland CL, Reichel CM, McGinty JF. Effects of oxytocin on methamphetamine-seeking exacerbated by predator odor pre-exposure in rats. Psychopharmacology. 2016;233:1015–24.

17. Shamay-Tsoory SG, Abu-Akel A. The social salience hypothesis of oxytocin. Biol Psychiatry. 2016;79:194–202.

18. Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry. 2016;79:213–21.

19. Stauffer CS, Moschetto JM, McKernan SM, Hsiang E, Borsari B, Woolley JD. Oxytocin-enhanced motivational interviewing group therapy for methamphetamine use disorder in men who have sex with men: study protocol for a randomized controlled trial. Trials. 2019;20:145.

20. Bowen MT, Carson DS, Spiro A, Arnold JC, McGregor IS. Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats. PloS One. 2011;6:e27237.

21. Hicks C, Cornish JL, Baracz SJ, Suraev A, McGregor IS. Adolescent pre‐treatment with oxytocin protects against adult methamphetamine‐seeking behavior in female rats. Addiction Biol 2016;21:304–15.

22. Baracz SJ, Everett NA, Cornish JL. The impact of early life stress on the central oxytocin system and susceptibility for drug addiction: applicability of oxytocin as a pharmacotherapy. Neurosci Biobehav Rev. 2018;pii: S0149-7634:30276–8.

23. Krasnova IN, Marchant NJ, Ladenheim B, McCoy MT, Panlilio LV, Bossert JM, et al. Incubation of methamphetamine and palatable food craving after punishment-induced abstinence. Neuropsychopharmacology. 2014;39:2008.

24. Wang G, Shi J, Chen N, Xu L, Li J, Li P, et al. Effects of length of abstinence on decision-making and craving in methamphetamine abusers. PloS ONE. 2013;8:e68791.

25. Reichel CM, Schwendt M, McGinty JF, Olive MF, See RE. Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology. 2011;36:782.

26. Hadamitzky M, Markou A, Kuczenski R. Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behavioural Brain Res. 2011;217:386–90.

27. Jang CG, Whitfield T, Schulteis G, Koob GF, Wee S. A dysphoric-like state during early withdrawal from extended access to methamphetamine self-administration in rats. Psychopharmacology. 2013;225:753–63.

28. Schwendt M, Reichel CM, See RE. Extinction-dependent alterations in corticostriatal mGluR2/3 and mGluR7 receptors following chronic methamphetamine self-administration in rats. PLoS One. 2012;7:e34299.

29. Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C, et al. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PloS ONE. 2010;5:e8790.

30. Havranek T, Zatkova M, Lestanova Z, Bacova Z, Mravec B, Hodosy J, et al. Intracerebroventricular oxytocin administration in rats enhances object recognition and increases expression of neurotrophins, microtubule‐associated protein 2, and synapsin I. J Neurosci Res. 2015;93:893–901.

31. Feifel D, Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology. 1999;141:93–98.

32. Manbeck KE, Shelley D, Schmidt CE, Harris AC. Effects of oxytocin on nicotine withdrawal in rats. Pharmacol Biochem Behav. 2014;116:84–89.

33. Qi J, Han WY, Yang JY, Wang LH, Dong YX, Wang F, et al. Oxytocin regulates changes of extracellular glutamate and GABA levels induced by methamphetamine in the mouse brain. Addiction Biol. 2012;17:758–69.

34. Peters ST, Bowen MT, Bohrer K, McGregor IS, Neumann ID. Oxytocin inhibits ethanol consumption and ethanol‐induced dopamine release in the nucleus accumbens. Addiction Biol. 2017;22:702–11.

35. Dumais KM, Kulkarni PP, Ferris CF, Veenema AH. Sex differences in neural activation following different routes of oxytocin administration in awake adult rats. Psychoneuroendocrinology. 2017;81:52–62.

36. Kogachi S, Chang L, Alicata D, Cunningham E, Ernst T. Sex differences in impulsivity and brain morphometry in methamphetamine users. Brain Struct Funct. 2017;222:215–27.

37. Venniro M, Caprioli D, Shaham Y. Animal models of drug relapse and craving: from drug priming-induced reinstatement to incubation of craving after voluntary abstinence. Prog brain Res. 2016;224:25–52.

38. Johnson AR, Thibeault KC, Lopez AJ, Peck EG, Sands LP, Sanders CM, et al. Cues play a critical role in estrous cycle-dependent enhancement of cocaine reinforcement. Neuropsychopharmacology. 2019;44:1189.

39. Moran-Santa Maria MM, McRae-Clark A, Baker NL, Ramakrishnan V, Brady KT. Yohimbine administration and cue-reactivity in cocaine-dependent individuals. Psychopharmacology 2014;231:4157–65.

40. Shepard JD, Bossert JM, Liu SY, Shaham Y. The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry. 2004;55:1082–9.

41. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217.

42. Belin D, Balado E, Piazza PV, Deroche-Gamonet V. Pattern of intake and drug craving predict the development of cocaine addiction-like behavior in rats. Biol psychiatry. 2009;65:863–8.

43. Mahoney JJ III, Hawkins RY, De La Garza R II, Kalechstein AD, Newton TF. Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants. Gend Med. 2010;7:414–21.

44. Rogers JL, De Santis S, See RE. Extended methamphetamine self-administration enhances reinstatement of drug seeking and impairs novel object recognition in rats. Psychopharmacology. 2008;199:615.

45. Schwendt M, Rocha A, See RE, Pacchioni AM, McGinty JF, Kalivas PW. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J Pharmacol Exp Therapeutics. 2009;331:555–62.

46. Fox HC, Sinha R. Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women. Harv Rev psychiatry. 2009;17:103–19.

47. Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186:356–61.

48. Venniro M, Zhang M, Shaham Y, Caprioli D. Incubation of methamphetamine but not heroin craving after voluntary abstinence in male and female rats. Neuropsychopharmacology. 2017;42:1126.

49. Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS. MDMA (“ecstasy”), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology. 2004;173:318–25.

50. Venniro M, Zhang M, Caprioli D, Hoots JK, Golden SA, Heins C, et al. Volitional social interaction prevents drug addiction in rat models. Nat Neurosci. 2018;21:1520.

51. Li X, Zeric T, Kambhampati S, Bossert JM, Shaham Y. The central amygdala nucleus is critical for incubation of methamphetamine craving. Neuropsychopharmacology. 2015;40:1297.

52. Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron. 2012;73:553–66.

53. Carson DS, Hunt GE, Guastella AJ, Barber L, Cornish JL, Arnold JC, et al. Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addiction Biol. 2010;15:448–63.

54. J Roberts-Wolfe D, W Kalivas. Glutamate transporter GLT-1 as a therapeutic target for substance use disorders. CNS Neurological Disord-Drug Targets. 2015;14:745–56.

55. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65:1–105.

56. Fischer KD, Houston AC, Rebec GV. Role of the major glutamate transporter GLT1 in nucleus accumbens core versus shell in cue-induced cocaine-seeking behavior. J Neurosci. 2013;33:9319–27.

57. Anker JJ, Carroll ME. Sex differences in the effects of allopregnanolone on yohimbine-induced reinstatement of cocaine seeking in rats. Drug Alcohol Depend. 2010;107:264–7.

58. Blyth BJ, Hauger RL, Purdy RH, Amico JA. The neurosteroid allopregnanolone modulates oxytocin expression in the hypothalamic paraventricular nucleus. Am J Physiol-Regulatory, Integr Comp Physiol. 2000;278:R684–91.

59. Steinman MQ, Duque-Wilckens N, Greenberg GD, Hao R, Campi KL, Laredo SA, et al. Sex-specific effects of stress on oxytocin neurons correspond with responses to intranasal oxytocin. Biol Psychiatry. 2016;80:406–14.

60. Chen YW, Fiscella KA, Bacharach SZ, Tanda G, Shaham Y, Calu DJ. Effect of yohimbine on reinstatement of operant responding in rats is dependent on cue contingency but not food reward history. Addiction Biol. 2015;20:690–700.

61. Nygard SK, Hourguettes NJ, Sobczak GG, Carlezon WA, Bruchas MR. Stress-induced reinstatement of nicotine preference requires dynorphin/kappa opioid activity in the basolateral amygdala. J Neurosci. 2016;36:9937–48.

62. Bowen MT, Neumann ID. Rebalancing the addicted brain: oxytocin interference with the neural substrates of addiction. Trends Neurosci. 2017;40:691–708.

63. Janezic EM, Uppalapati S, Nagl S, Contreras M, French ED, Fellous JM. Beneficial effects of chronic oxytocin administration and social co-housing in a rodent model of post-traumatic stress disorder. Behavioural Pharmacol. 2016;27:704–17.

64. Peters S, Slattery DA, Uschold-Schmidt N, Reber SO, Neumann ID. Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice. Psychoneuroendocrinology. 2014;42:225–36.

65. Baracz SJ, Parker LM, Suraev AS, Everett NA, Goodchild AK, McGregor IS, et al. Chronic methamphetamine self‐administration dysregulates oxytocin plasma levels and oxytocin receptor fibre density in the nucleus accumbens core and subthalamic nucleus of the rat. J Neuroendocrinol. 2016;28. https://onlinelibrary.wiley.com/doi/full/10.1111/jne.12337.

66. Georgiou P, Zanos P, Garcia-Carmona JA, Hourani S, Kitchen I, Laorden ML, et al. Methamphetamine abstinence induces changes in μ-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype. Neuropharmacology. 2016;105:520–32.

67. Buisman-Pijlman FT, Sumracki NM, Gordon JJ, Hull PR, Carter CS, Tops M. Individual differences underlying susceptibility to addiction: role for the endogenous oxytocin system. Pharmacol Biochem Behav. 2014;119:22–38.

68. Bowen MT, Liu J, Buisman-Pijlman FT. Oxytocin: providing new avenues for treating and understanding problematic drug use. Neuropathol Drug Addict Subst Misuse. 2018;3:82–92.

69. Tunstall BJ, Kirson D, Zallar LJ, McConnell SA, Vendruscolo JC, Ho CP, et al. Oxytocin blocks enhanced motivation for alcohol in alcohol dependence and blocks alcohol effects on GABAergic transmission in the central amygdala. PLoS Biol. 2019;17:e2006421.

70. Cadet JL. Animal models of addiction: compulsive drug taking and cognition. Neurosci Bio-behav Rev. 2019;106:5–6. https://www.ncbi.nlm.nih.gov/pubmed/31176644.

71. Jard S, Barberis C, Audigier S, Tribollet E. Neurohypophyseal hormone receptor systems in brain and periphery. Prog Brain Res. 1987;72:173–87.

72. Smith AS, Korgan AC, Young WS. Oxytocin delivered nasally or intraperitoneally reaches the brain and plasma of normal and oxytocin knockout mice. Pharmacol Res. 2019;146:104324.

73. Yamamoto Y, Liang M, Munesue S, Deguchi K, Harashima A, Furuhara K, et al. Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice. Communications. Biology. 2019;2:76.

74. Iwasaki Y, Kumari P, Wang L, Hidema S, Nishimori K, Yada T. Relay of peripheral oxytocin to central oxytocin neurons via vagal afferents for regulating feeding. Biochemical Biophysical Res Commun. 2019;519:553–8.

75. Ramos L, Hicks C, Kevin R, Caminer A, Narlawar R, Kassiou M, et al. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3, 4-methylenedioxymethamphetamine in rats: involvement of the V1 A receptor. Neuropsychopharmacology. 2013;38:2249.

76. Westenbroek C, Perry AN, Jagannathan L, Becker JB. Effect of social housing and oxytocin on the motivation to self-administer methamphetamine in female rats. Physiol Behav. 2017;203:10–17.

77. Guastella AJ, Howard AL, Dadds MR, Mitchell P, Carson DS. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009;34:917–23.

78. Jurek B, Neumann ID. The oxytocin receptor: from intracellular signaling to behavior. Physiological Rev. 2018;98:1805–908.

79. Roberts BZ, Young JW, He YV, Cope ZA, Shilling PD, Feifel D. Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats. Neuropharmacology. 2019;150:15–26.